Last reviewed · How we verify

Beyfortus — Competitive Intelligence Brief

Beyfortus (Beyfortus) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Respiratory.

marketed Fusion glycoprotein F0 Respiratory Biologic Live · refreshed every 30 min

Target snapshot

Beyfortus (Beyfortus) — National Institute of Allergy and Infectious Diseases (NIAID).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Beyfortus TARGET Beyfortus National Institute of Allergy and Infectious Diseases (NIAID) marketed Fusion glycoprotein F0
BEYFORTUS NIRSEVIMAB-ALIP ASTRAZENECA AB marketed Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC] Fusion glycoprotein F0

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Beyfortus — Competitive Intelligence Brief. https://druglandscape.com/ci/beyfortus. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: